Pharmasaga Showcases Novel Diabetes Candidate PS1 at Silicon Valley's Taiwan Venture Day

Pharmasaga Takes the Stage at Silicon Valley's Taiwan Venture Day, Featured in On-Site Interview by Epoch Times

On July 23 (PST), Pharmasaga participated in Taiwan Venture Day in Silicon Valley, marking a major milestone in bringing Taiwanese novel drug development to the global stage. During the event, Pharmasaga founder Sunny Lee was featured in an exclusive on-site interview with Epoch Times, highlighting the company's scientific breakthroughs and strategic vision.

Key Highlights from the Showcase:

• Disease-Modifying Mechanism: Pharmasaga presented its flagship small-molecule candidate, PS1 (PS-001). Designed to protect and preserve pancreatic beta-cell quantity and function, PS1 addresses underlying disease mechanisms to explore possibilities for delaying or reversing Type 2 Diabetes.
• Clinical Progress: Following the successful completion of Phase 1 clinical trials—which demonstrated favorable safety and promising preliminary blood glucose-lowering effects—Pharmasaga is currently advancing applications for multi-regional, multi-center Phase 2 clinical trials across three countries.
• Elevating Taiwan's Global Tech Impact: Beyond Taiwan's renowned semiconductor leadership, Pharmasaga aims to demonstrate that Taiwan is equally capable of pioneering world-class biomedical innovations that address global healthcare needs.

We extend our sincere thanks to Epoch Times and all the investors and partners who connected with us in Silicon Valley as we continue to advance PS1 through global clinical development.